Industry News

Amgen on Friday declared a dividend of USD1.00 per share for the third quarter of 2016.. Stockholders of record at the close of business as of 17 August 2016 will receive the dividend payment on 8 September 2016.. Amgen is engaged in discovering, developing, manufacturing and delivering innovative human therapeutics by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology."/>
Amgen's board sets dividend payment date of 8 September 2016
MorphoSys AG will publish its first six months' 2016 results on August 1, 2016 at 7:00 am CEST. At 2:00 pm CEST, the Management Board of MorphoSys AG will host a public conference call and webcast to present MorphoSys's Half-Year Report 2016 and provide further details on the Company's latest developments. Dial-in numbers: Germany: +49 89 2444 32975 United Kingdom: +44 20 3003 2666 USA: +1 202 204 1514."/>
MorphoSys to Host Q2 2016 Conference Call on August 1, 2016
NewLink Genetics Corporation, announced today that Merck, known as MSD outside the United States and Canada, has reached two key regulatory milestones for the Ebola Zaire vaccine candidate known as V920. The U.S Food and Drug Administration has granted the vaccine candidate Breakthrough Therapy Designation, and the European Medicines Agency has provided the vaccine candidate PRIME status.. V920 was initially engineered by scientists from the Public..."/>
NewLink Genetics Announces Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
MediciNova revealed on Friday the receipt of a Notice of Allowance from the US Patent and Trademark Office for a pending patent application that covers MN-001 and MN-002 for the treatment of a broad range of fibrosis/fibrotic disease in different organs due to different causes. Upon issuance, the US patent maturing from this allowed patent application is expected to expire no earlier than June 2035, added the company. The company said the allowed..."/>
MediciNova wins USPTO's notice of allowance for new patent covering MN-001 and MN-002 for treating fibrosis
Biocept, Inc., a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces that it will release financial results for the three and six months ended June 30, 2016 before the market opens on Tuesday, August 2, 2016. The Company will also host a conference call for the investment community to discuss the results and answer questions at 11:00 a.m. Eastern time."/>
Biocept to Release Second Quarter Financial Results on August 2, 2016 and Host Investor Conference Call at 11:00 a.m. Eastern Time
NantHealth. CULVER CITY, Calif.---- NantHealth, Inc.,, a leading next-generation, evidence-based, personalized healthcare company, today announced that it has partnered with the University of Utah in analyzing the entire genomic profiles of at least 1,000 individuals who have a history of rare and life-threatening diseases and..."/>
NantHealth and University of Utah Establish Heritage 1K Project to Discover Genetic Causes of 25 Rare and Common Diseases
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that Alnylam and collaborators will present interim results from the ongoing Phase 1 clinical trial with fitusiran, an investigational RNAi therapeutic targeting antithrombin for the..."/>
Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress
Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient in the Phase 2 ULTRA study was dosed at Stanford University. The ULTRA study will evaluate the effects of ubenimex in patients with secondary lymphedema of the lower limb who are optimized on physical therapies. Physical therapies, such as compression garments and bandaging,..."/>
Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema
Foamix Pharmaceuticals Ltd.,, a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce second quarter ended June 30, 2016 financial results and host a conference call and webcast on Wednesday, August 10.. Conference Call& Webcast Wednesday, August 10, 2016@ 8:30am Eastern Time."/>
Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for Wednesday, August 10
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced top-line 24- week data demonstrating persistent migraine prevention in a Phase 2 b clinical trial evaluating ALD403 in patients with chronic migraine. ALD403 is Alder’ s proprietary monoclonal antibody product candidate for migraine prevention that targets calcitonin gene-related peptide."/>
Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine
Flexion Therapeutics, Inc. announced today that it will host a conference call and webcast to report its second-quarter 2016 financial results on Wednesday, August 3, 2016, at 4:30 p.m. ET.. The dial-in number for the conference call is 770-0022 for domestic participants and 982-4677 for international participants, with Conference ID #55311625. A live webcast of the conference call can also be accessed through the“ Investors” tab on the Flexion..."/>
Flexion Therapeutics to Report Second-Quarter 2016 Financial Results on August 3, 2016
Aphria Inc. announced today that it closed on a $6 million financing with WFCU Credit Union. The financing is comprised of three separate facilities: a mortgage; a term loan; and an operating line of credit. At closing, Aphria drew $5,000,000 under the various facilities."/>
Aphria Secures $6 Million Loan Facility Planning for Continued Capacity Growth
Celsion Corporation today announced data from the second cohort of patients in its Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. In the first six patients dosed, GEN-1 plus standard chemotherapy produced..."/>
Celsion Announces Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Ovarian Cancer Patients
Intrexon Corporation, a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today introduced its Florian™ technology, an "on-off" regulation switch enabling a variety of commercial applications in agriculture. The platform, developed at Intrexon, furthers the Company's position in inducible control and regulation of genes for bio-based products spanning therapeutics, gene..."/>
Intrexon Introduces Florian™ Switch Technology for Flowering Control
Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the U.S. Food and Drug Administration has accepted the company’ s Investigational New Drug application for CB-1158 for the treatment of solid tumors. CB-1158 is a first-in-class, orally..."/>
Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced the completion of patient enrollment in its two Phase 3 pivotal clinical trials and its Phase 3 open-label safety trial of its lead candidate, A-101 Topical Solution for the treatment of seborrheic keratosis. Aclaris expects to report initial results from each of the three Phase 3 trials in the fourth quarter of 2016.. A-101 is a proprietary..."/>
Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis (SK); Provides Update on Clinical Programs
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, August 4, 2016, to provide a corporate update and discuss details of the Company’ s financial results for the quarter ended June 30, 2016.. To access the live conference call via phone, dial..."/>
Intra-Cellular Therapies to Host Second Quarter 2016 Financial Results Conference Call and Webcast
OmniComm Systems, Inc., a global leading provider of clinical data management technology, announces that on Thursday, July 28, 2016, at 11 am EDT, OmniComm will host a complimentary webinar featuring Ken Light, EVP of Transformation and Professional Services at OmniComm Systems and Jennifer Plumer, Pharma/CRO Lead at Validic, as the keynote speakers. In this webinar Jennifer Plumer, Pharma/CRO Lead, Validic, and Ken Light, EVP of Transformation..."/>
OmniComm Systems to Present with Validic on Digital Health and the Emerging Vital Role of Electronic Data Capture
Penumbra, Inc., a global interventional therapies company, today announced U.S. commercial availability of its most advanced thrombectomy device, the ACE™ 68 Reperfusion Catheter, part of the fully integrated Penumbra System ®, at the Society of NeuroInterventional Surgery 13th Annual Meeting in Boston, Massachusetts. This Smart News Release features..."/>
Penumbra Launches Newest Stroke Thrombectomy Technology ACE™68 Reperfusion Catheter at SNIS 2016
Ocular Therapeutix, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it received a Complete Response Letter from the U.S."/>
Ocular Therapeutix™ Receives Complete Response Letter from FDA for its NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain
Cocrystal Pharma reported on Friday the appointment of Dr Gary Wilcox as interim chief executive officer. Effective immediately, Dr Wilcox succeeds Jeffrey Meckler, who has stepped down as the company's chief executive officer and board member to pursue other interests. In addition, Dr Wilcox will continue to serve as the vice chairman of the board of directors of the company."/>
Cocrystal names Dr Gary Wilcox as interim CEO

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials565 Articles
Consumer Discretionary509 Articles
Information Technology504 Articles
Industrials383 Articles
Health Care336 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at